par Michiels, Sandra
;Bron, Dominique
;Crombez, Patrick;Vercruyssen, Marie
;Tricas-Sauras, Sandra
;Kirakoya, Fati 
Editeur scientifique Michiels, Sandra
;Bron, Dominique
;Crombez, Patrick;Vercruyssen, Marie
;Tricas-Sauras, Sandra
;Kirakoya, Fati 
Référence Annual Meeting of the European Society for Blood and Marrow Transplantation(The 45th: 24-27 march 2019), O185 Oral anticancer medication adherence of migrants and ethnic minorities with haematological malignancies, a challenge for EBMT?, Bone Marrow Transplantation, Quality Management Group – Oral Session, Vol. 54, page (678–680)
Publication Publié, 2019
;Bron, Dominique
;Crombez, Patrick;Vercruyssen, Marie
;Tricas-Sauras, Sandra
;Kirakoya, Fati 
Editeur scientifique Michiels, Sandra
;Bron, Dominique
;Crombez, Patrick;Vercruyssen, Marie
;Tricas-Sauras, Sandra
;Kirakoya, Fati 
Référence Annual Meeting of the European Society for Blood and Marrow Transplantation(The 45th: 24-27 march 2019), O185 Oral anticancer medication adherence of migrants and ethnic minorities with haematological malignancies, a challenge for EBMT?, Bone Marrow Transplantation, Quality Management Group – Oral Session, Vol. 54, page (678–680)
Publication Publié, 2019
Abstract de conférence
| Résumé : | Background: Migration is increasing worldwide, with accumulating evidence of disparities. Migrants and Ethnic Minorities (MEMs) are identified as one of the most vulnerable group in health provision. In the context of haematological cancer patients (HECPs), significant “racial” and ethnic disparities have been reported regarding incidence and survival rates. At the same time, HECPs are increasingly treated by Oral Anticancer Medications (OAMs), including for bridging to transplant, and oncohaematological teams have to deal with the survey of adherence. These two evolutions raise the question of MEMs' adherence and their integration in cancer adherence studies.Methods: We conducted a scoping review of scientific literature regarding adherence to treatment in MEMs patients, particularly to OAMs.Results: Data are still scarce regarding how cancer patients adhere to their medication plan, particularly for those with malignancies other than breast cancer.In HECPs, research has shown that poor adherence impacts the quality of response and the risk of relapse.Nowadays, adherence is understood as the complex interplay between predisposing factors, patients' knowledge and beliefs, and interactions between patients and clinicians.Recent findings underline differences and difficulties between physician and patient coming from different cultural and/or ethnic backgrounds. Little is known about miscommunication causes. This is not only a language issue but it is also intimately related to cultural differences in the way people think about health, disease and care.It would seem therefore reasonable to anticipate higher risk of poor adherence among MEMs in foreign context. Unfortunately, this population group seems to have been forgotten from adherence studies in oncology.If “race” or ethnicity have been frequently reported to be a predictor of poor adherence, these studies entail important limitations which prevent definite conclusions. Beyond the fact that most research studies concern other chronic diseases, they are mainly conducted in USA and include socioeconomic factors such as uninsured driving that may interact with ethnicity in explaining nonadherence prevalence. Most adherence studies do not report patients' ethnic background either. In general, as for other cancer clinical trials, MEMs appear particularly underrepresented (2-11%).Conclusions: The results of this scoping review highlight important gaps in knowledge and research concerning MEMs' adherence.Their underrepresentation in adherence studies risks the generalizability of results in the context of diverse minority populations.Additionally, geographical concentration of data in Anglo-Saxon countries and regarding other chronic diseases raises the question of results' applicability to HECPs and for other countries.With the emergence of novel oral therapeutics in oncohaematology it becomes urgent to identify differences in access, use and quality of care that may lead to disparities in health outcomes. As an expert association, EBMT can play a key role in answering these unmet needs. EBMT should recognize existing disparities and contribute to the development of guidelines supporting the inclusion of MEMs and other underrepresented populations in oncohaematology adherence studies. By supporting extensive research EBMT would contribute to provide urgent missing data about how MEMs with haematological malignancies adhere and persist to their OAM in our European contexts and to develop consistent strategies. |



